Targeting triple-negative breast cancer: Optimising therapeutic outcomes

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2223-2234

  Gelmon, K ^a,b   Dent, R ^c,d   Mackey, J R ^e,f   Laing, K ^g,h   Mcleod, D ⁱ   Verma, S ^j,k  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c National Cancer Center Singapore   (Canada)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e UNIVERSITY OF ALBERTA   (Canada)

^f CROSS CANCER INSTITUTE   (Canada)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^h Eastern Health Canada   (Canada)

ⁱ Kaleidoscope Strategic   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k SUNNYBROOK RESEARCH INSTITUTE   (Canada)

more..

Author keywords

Basal like; Breast cancer; Cancer treatment; Systematic review; Targeted therapy; Triple negative

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; GEMCITABINE; INIPARIB; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; PACLITAXEL; PLACEBO; SORAFENIB; SUNITINIB;

BLEEDING; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MOLECULARLY TARGETED THERAPY; NEUROTOXICITY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMATITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT;

EID: 84865573852     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds067     Document Type: Review

References (119)

1. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
2. Lehmann BD, Bauer JA, Chen X et al. Transcriptome analysis of triple negative breast cancers identifies six distinct biological subgroups and reveals therapeutic strategies. Cancer Res 2010; 70: (Abstr PD01-07, presented data-SABCS 2010).
3. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
4. Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
5. Perou CM Molecular stratification of triple-negative breast cancers. Oncologist 2011; 16Suppl 161-70.
6. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
7. Bertucci F, Finetti P, Cervera N et al. How basal are triple-negative breast cancers?. Int J Cancer 2008; 123: 236-240.
8. Kreike B, van Kouwenhove M, Horlings H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65.
9. Prat A, Perou CMDeconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
10. Atchley DP, Albarracin CT, Lopez A et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26: 4282-4288.
11. Gonzalez-Angulo AM, Timms KM, Liu S et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17: 1082-1089.
12. Turner N, Tutt A, Ashworth AHallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819.
13. Miyoshi Y, Murase K, Oh KBasal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol 2008; 13: 395-400.
14. Abd El-Rehim DM, Ball G, Pinder SE et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116: 340-350.
15. Beger C, Pierce LN, Kruger M et al. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci U S A 2001; 98: 130-135.
16. Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26: 2126-2132.
17. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-5657.
18. Kassam F, Enright K, Dent R et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009; 9: 29-33.
19. Onitilo AA, Engel JM, Greenlee RT, Mukesh BNBreast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009; 7: 4-13.
20. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
21. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
22. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
23. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
24. Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007; 109: 1721-1728.
25. Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109: 123-139.
26. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
27. Smid M, Wang Y, Zhang Y et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008; 68: 3108-3114.
28. Heitz F, Harter P, Lueck HJ et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009; 45: 2792-2798.
29. Dowsett M, Allred C, Knox J et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008; 26: 1059-1065.
30. Comen E, Davids M, Kirchhoff T et al. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi women. Breast Cancer Res Treat 2011; 129: 185-190.
31. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214.
32. Thompson LH, Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res 2001; 477: 131-153.
33. Dantzer F, de La Rubia G, Menissier-De Murcia J et al. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry (Mosc) 2000; 39: 7559-7569.
34. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374.
35. Bhattacharyya GS, Basu S, Agarwal V et al. Single institute phase II study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple-negative. Eur J Cancer 2009; 7: 18. (Abstr 41LBA, presented data-ECCO 15-ESMO 34 2009).
36. Carey LA, Rugo HS, Marcom PK et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008; 26: (Abstr 1009, presented data-ASCO Annual Meeting 2008).
37. O'Shaughnessy J, Schwartzberg LS, Danso MA et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011; 29: (Abstr 1007, presented data-ASCO Annual Meeting 2011).
38. Maisano R, Zavettieri M, Azzarello D et al. Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study. J Chemother 2011; 23: 40-43.
39. Wang Z, Hu X, Chen L et al. Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: preliminary results report of a phase II trial. J Clin Oncol 2010; 28: (Abstr 1100).
40. Alba E, Chacon JI, Lluch A et al. Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03-A multicenter, randomized phase II study. J Clin Oncol2011; 29: (Abstr 1015, presented data-ASCO Annual Meeting 2011).
41. Isakoff SJ, Goss PE, Mayer EL et al. TBCRC009: a multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol 2011; 29: (Abstr 1025, presented data-ASCO Annual Meeting 2011).
42. Kim T, Lee H, Han S et al. The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triplenegative metastatic breast cancer. J Clin Oncol 2010; 28: (Abstr 1071).
43. Baselga J, Stemmer S, Pego A et al. Cetuximab + cisplatin in estrogen receptornegative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res 2010; 70: (Abstr PD01-01, presented data-SABCS 2010).
44. Hamilton EP, Kimmick GG, Desai N et al. Use of SPARC, EGFR, and VEGFR expression to predict response to nab-paclitaxel (nabP)/carboplatin (C)/ bevacizumab (B) chemotherapy in triple-negative metastatic breast cancer (TNMBC). J Clin Oncol 2010; 28: (Abstr 1109).
45. O'Shaughnessy J, Weckstein D, Vukelja S et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 106: S32. (Abstr 308, presented data-SABCS 2007).
46. Ryan PD, Tung NM, Isakoff SJ et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy. J Clin Oncol 2009; 27: (Abstr 551, presented data-ASCO Annual Meeting 2009).
47. Sharma P, Khan QJ, Kimler BF et al. Results of a phase II study of neoadjuvant platinum/taxane based chemotherapy and erlotinib for triple negative breast cancer. Cancer Res 2010; 70: (Abstr P1-11-07, presented data-SABCS 2010).
48. Frasci G, Comella P, Rinaldo M et al. Preoperative weekly cisplatin-epirubicin- paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2009; 20: 1185-1192.
49. Torrisi R, Balduzzi A, Ghisini R et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008; 62: 667-672.
50. Chen XS, Nie XQ, Chen CM et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 2010; 21: 961-967.
51. Miranda AA, Lara Medina FU, Arce C et al. Phase II open, single-arm trial: cisplatin combined with paclitaxel and doxorubicin in operable or locally advanced triple-negative breast cancer. J Clin Oncol 2011; 29: (Abstr 1135, presented data-ASCO Annual Meeting 2011).
52. Lokich J, Anderson NCarboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9: 13-21.
53. Sanborn RE. Cisplatin versus carboplatin in NSCLC: is there one "best" answer?. Curr Treat Options Oncol 2008; 9: 326-342.
54. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
55. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
56. Isakoff SJ, Overmoyer B, Tung NM et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010; 28: (Abstr 1019, presented data-ASCO Annual Meeting 2010).
57. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-861.
58. Dent RA, Lindeman GJ, Clemons M et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010; 28: (Abstr 1018, presented data-ASCO Annual Meeting 2010).
59. Loesch D, Asmar L, McIntyre K et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer 2008; 8: 178-186.
60. Rajan A, Gutierrez M, Kummar S et al. A phase I combination study of AZD2281 and cisplatin plus gemcitabine in adults with solid tumors. Ann Oncol 2009; 20: (Abstr G04, presented data-7th International Symposium on Targeted Anticancer Therapies).
61. Giaccone G, Rajan A, Kelly RJ et al. A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors. J Clin Oncol 2010; 28: (Abstr 3027, presented data-ASCO Annual Meeting 2010).
62. Tan AR, Gibbon D, Stein MN et al. Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide. J Clin Oncol 2010; 28: (Abstr 3000, presented data-ASCO Annual Meeting 2010).
63. Kummar S, Chen AP, Ji JJ et al. A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas. J Clin Oncol 2010; 28: (Abstr 2605).
64. Linderholm BK, Hellborg H, Johansson U et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009; 20: 1639-1646.
65. O'Shaughnessy J, Dieras V, Glaspy J et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). Cancer Res 2009; 69: (Abstr 207, presented data-SABCS 2009).
66. Brufsky A, Valero V, Tiangco B et al. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): analysis of RIBBON-2. J Clin Oncol 2011; 29: (Abstr 1010, presented data-ASCO Annual Meeting 2011).
67. Curigliano G, Pivot X, Cortes J et al. A randomized phase II study of sunitinib vs. standard of care for patients with previously treated advanced triple-negative breast cancer. Cancer Res 2010; 70: (Abstr P6-12-02, presented data-SABCS 2010).
68. Gomez P, Roche H, Costa F et al. Overall survival data from SOLTI-0701: a multinational, double-blind, placebo-controlled, randomized phase 2b study evaluating the oral combination of sorafenib and capecitabine in patients with locally advanced or metastatic HER2-negative breast cancer. Cancer Res 2010; 70: (Abstr P2-16-01, presented data-SABCS 2010).
69. Baselga J, Roche H, Costa F et al. SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res 2009; 69: (Abstr 45, presented data-SABCS 2009).
70. Hudis C, Tauer KW, Hermann RC et al. Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV). J Clin Oncol 2011; 29: (Abstr 1009, presented data-ASCO Annual Meeting 2011).
71. Finn RS, Press MF, Dering J et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 2009; 27: 3908-3915.
72. O'Shaughnessy J, Romieu G, Diéras V et al. Meta-analysis of patients with triplenegative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res 2010; 70: (Abstr P6-12-03, presented data-SABCS 2010).
73. Choueiri TK, Mayer EL, Je Y et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011; 29: 632-638.
74. Cuppone F, Bria E, Sperduti I et al. Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): metaregression analysis of randomized trials (RCT). J Clin Oncol 2010; 28: (Abstr 1045, presented data-ASCO Annual Meeting 2010).
75. Goozner MAvastin hearing leads to more uncertainty over drug's future. J Natl Cancer Inst 2011; 103: 1148-1150.
76. von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
77. Bear HD, Tang G, Rastogi P et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011; 29: (Abstr LBA 1005, presented data-ASCO Annual Meeting 2011).
78. Miller KD, O'Neill A, Perez EA et al. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol 2008; 26: 520.
79. McArthur HL, Rugo H, Nulsen B et al. Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer. Cancer Res 2009; 69: 281S-282S: (Abstr 4104, presented data-SABCS 2008).
80. Morris PG, Dickler M, McArthur HL et al. Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol 2009; 27: 6117-6123.
81. Miller KD, O'Neill A, Perez EA et al. A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Ann Oncol 2012; 23: 331-337.
82. Cancernetwork. comAvastin breast Rx trial enrollment halted due to cardiotoxicity cases. Oncology NEWS International 2009; 18: 10.
83. Barrios CH, Liu MC, Lee SC et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010; 121: 121-131.
84. Wildiers H, Fontaine C, Vuylsteke P et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010; 123: 463-469.
85. Burstein HJ, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810-1816.
86. Mayer EL, Dhakil S, Patel T et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010; 21: 2370-2376.
87. Crown J, Dieras V, Staroslawska E et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010; 28: (Abstr LBA1011, presented data-ASCO Annual Meeting 2010).
88. Bergh J, Greil R, Voytko N et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010; 28: (Abstr LBA1010, presented data-ASCO Annual Meeting 2010).
89. Moreno-Aspitia A, Morton RF, Hillman DW et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009; 27: 11-15.
90. Bianchi G, Loibl S, Zamagni C et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009; 20: 616-624.
91. Bondarde S, Kaklamani V, Prasad Sahoo T et al. Sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer: overall survival results from a double-blind, randomized, placebocontrolled, phase 2b trial. Cancer Res 2010; 70: (Abstr P2-16-03, presented data-SABCS 2010).
92. Gerber B, Eidtmann H, Rezai M et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: secondary endpoint analysis of the GeparQuinto study (GBG 44). ASCO Meeting Abstracts 2011; 29: (Abstr 1006, presented data-ASCO Annual Meeting 2011).
93. Tan DSP, Marchió C, Jones RL et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008; 111: 27-44.
94. Viale G, Rotmensz N, Maisonneuve P et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009; 116: 317-328.
95. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
96. Bernsdorf M, Ingvar C, Jorgensen L et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat 2011; 126: 463-470.
97. Noh WC, Mondesire WH, Peng J et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004; 10: 1013-1023.
98. Yu K, Toral-Barza L, Discafani C et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-258.
99. Mayer I, Burris H, Bendell J et al. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Cancer Res 2009; 69: (Abstr 3093, presented data-SABCS 2009).
100. Andre F, Campone M, O'Regan R et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010; 28: 5110-5115.
101. Gonzalez-Angulo AM, Green MC, Murray JL et al. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). J Clin Oncol 2011; 29: (Abstr 1016, presented data-ASCO Annual Meeting 2011).
102. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
103. O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly (ADPribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/ carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009; 27: (Abstr 3, presented data-ASCO Annual Meeting 2009).
104. Pal SK, Childs BH, Pegram MTriple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011; 125: 627-636.
105. Carey L, O'Shaughnessy J, Hoadley K et al. Potential predictive markers of benefit from cetuximab in metastatic breast cancer: an analysis of two randomized phase 2 trials. Cancer Res 2009; 69: (Abstr 2014, presented data -SABCS 2009).
106. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
107. Sirohi B, Arnedos M, Popat S et al. Platinum-based chemotherapy in triplenegative breast cancer. Ann Oncol 2008; 19: 1847-1852.
108. Foulkes WD, Brunet JS, Stefansson IM et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53 + /glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer. Cancer Res 2004; 64: 830-835.
109. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423.
110. de Ruijter TC, Veeck J, de Hoon JP et al. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2011; 137: 183-192.
111. Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009; 115: 359-363.
112. Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
113. Curtin N. JPARP inhibitors for cancer therapy. Expert Rev Mol Med 2005; 7: 1-20.
114. Ji J, Lee MP, Kadota M et al. Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201. AACR Meeting Abstracts 20114527.
115. Browder T, Butterfield CE, Kraling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-1886.
116. Shen FZ, Wang J, Liang J et al. Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?. Int J Exp Pathol 2010; 91: 10-16.
117. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26: 4672-4678.
118. Jubb AM, Miller KD, Rugo HS et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011; 17: 372-381.
119. Mendes-Pereira AM, Martin SA, Brough R et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 315-322.